Xiu-Xiu Sun1,2, Su-Su Li1,2, Man Zhang1,2, Qiao-Mei Xie1,2, Jian-Hua Xu3, Sheng-Xiu Liu4, Yuan-Yuan Gu1,2, Fa-Ming Pan1,2, Jin-Hui Tao5, Sheng-Qian Xu3, Shuang Liu3, Jing Cai3, De-Guang Wang6, Long Qian7, Chun-Huai Wang7, Li Lian3, Hui Xiao3, Pei-Ling Chen3, Chun-Mei Liang8, You-Bing Fang9, Qiang Zhou10, Hai-Liang Huang11, Hong Su1,2, Hai-Feng Pan1,2, Dong-Qing Ye1,2, Yan-Feng Zou1,2. 1. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University Hefei 230032, Anhui, China. 2. The Key Laboratory of Major Autoimmune Diseases Hefei 230032, Anhui, China. 3. Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China. 4. Institute of Dermatology and Department of Dermatology, The First Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China. 5. Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital Hefei 230001, Anhui, China. 6. Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China. 7. Department of Rheumatology and Immunology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China. 8. Department of Laboratory Medicine, School of Public Health, Anhui Medical University Hefei 230032, Anhui, China. 9. Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University Hefei 230022, Anhui, China. 10. Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China. 11. Department of Biochemistry and Molecular Biology, School of Basic Medicine, Anhui Medical University Hefei 230032, Anhui, China.
Abstract
Objective: The aim of this study was to investigate the associations between HSP90B1 gene polymorphisms and the efficacy of glucocorticoids (GCs) and the improvement of health-related quality of life (HRQoL) in Anhui patients with systemic lupus erythematosus (SLE). Method: A total of 305 patients with SLE were recruited to the study. These patients were treated with GCs for 12 weeks and classified into two groups (sensitivity and insensitivity) according to the response to GCs measured by the scores on SLE disease activity index (SLEDAI). The HRQoL of SLE patients were evaluated by 36-item Short Form Health Survey (SF-36) at baseline and 12 weeks respectively. HapMap database and Haploview software were used to select HSP90B1 gene tag single nucleotide polymorphisms (SNPs). Benjamini & Hochberg (BH) method based on false discovery rate (FDR) was used for multiple testing correction. Results: A total of 291 patients were included in final data analysis with 14 patients excluded due to loss to follow-up. Among these patients, 160 patients were sensitive to GCs and 131 patients were insensitive to GCs. Twelve tag SNPs of HSP90B1 gene were selected. The rs12426382 polymorphism was associated with the efficacy of GCs (dominant model: crude OR=0.514, 95% CI=0.321-0.824, P=0.006; adjusted OR=0.513, 95% CI=0.317-0.831, P=0.007). After BH correction, there was no association between rs12426382 polymorphism and efficacy of GCs (PBH =0.084). In haplotype analysis, the haplotype CCCGAACATCCC (OR=2.273, 95% CI=1.248-4.139, P=0.006) and CTGGGACGTTC (OR=0.436, 95% CI=0.208-0.916, P=0.025) showed significant associations with the efficacy of GCs. After corrected by BH method, CCCGAACATCCC was still associated with the efficacy of GCs (PBH =0.048). The rs3794241, rs1165681, rs2722188, rs3794240 and rs10861147 polymorphisms were associated with the improvement of HRQoL among SLE patients (P < 0.05). But no association existed after the correction of BH method (P > 0.05). Conclusions: The results of this study demonstrated that HSP90B1 genetic polymorphisms might be associated with the efficacy of GCs, but not associated with the improvement of HRQoL in Anhui population with SLE.
Objective: The aim of this study was to investigate the associations between HSP90B1 gene polymorphisms and the efficacy of glucocorticoids (GCs) and the improvement of health-related quality of life (HRQoL) in Anhui patients with systemic lupus erythematosus (SLE). Method: A total of 305 patients with SLE were recruited to the study. These patients were treated with GCs for 12 weeks and classified into two groups (sensitivity and insensitivity) according to the response to GCs measured by the scores on SLE disease activity index (SLEDAI). The HRQoL of SLEpatients were evaluated by 36-item Short Form Health Survey (SF-36) at baseline and 12 weeks respectively. HapMap database and Haploview software were used to select HSP90B1 gene tag single nucleotide polymorphisms (SNPs). Benjamini & Hochberg (BH) method based on false discovery rate (FDR) was used for multiple testing correction. Results: A total of 291 patients were included in final data analysis with 14 patients excluded due to loss to follow-up. Among these patients, 160 patients were sensitive to GCs and 131 patients were insensitive to GCs. Twelve tag SNPs of HSP90B1 gene were selected. The rs12426382 polymorphism was associated with the efficacy of GCs (dominant model: crude OR=0.514, 95% CI=0.321-0.824, P=0.006; adjusted OR=0.513, 95% CI=0.317-0.831, P=0.007). After BH correction, there was no association between rs12426382 polymorphism and efficacy of GCs (PBH =0.084). In haplotype analysis, the haplotype CCCGAACATCCC (OR=2.273, 95% CI=1.248-4.139, P=0.006) and CTGGGACGTTC (OR=0.436, 95% CI=0.208-0.916, P=0.025) showed significant associations with the efficacy of GCs. After corrected by BH method, CCCGAACATCCC was still associated with the efficacy of GCs (PBH =0.048). The rs3794241, rs1165681, rs2722188, rs3794240 and rs10861147 polymorphisms were associated with the improvement of HRQoL among SLEpatients (P < 0.05). But no association existed after the correction of BH method (P > 0.05). Conclusions: The results of this study demonstrated that HSP90B1 genetic polymorphisms might be associated with the efficacy of GCs, but not associated with the improvement of HRQoL in Anhui population with SLE.
Authors: Qi-Quan Huang; Rudina Sobkoviak; Angela R Jockheck-Clark; Bo Shi; Arthur M Mandelin; Paul Peter Tak; G Kennith Haines; Christopher V Nicchitta; Richard M Pope Journal: J Immunol Date: 2009-04-15 Impact factor: 5.422
Authors: V M Kushnir; B Cassell; C P Gyawali; R D Newberry; P Kibe; B D Nix; A Sabzpoushan; N D Kanuri; G S Sayuk Journal: Aliment Pharmacol Ther Date: 2013-06-20 Impact factor: 8.171